Abstract
Since the introduction of highly active antiretroviral therapy more than 2 decades ago, HIV-related deaths have dramatically decreased and HIV infection has become a chronic disease. Due to the inability of antiretroviral drugs to eradicate the virus, treatment of HIV infection requires a systemic lifelong therapy. However, even when successfully treated, HIV patients still show increased incidence of age-associated co-morbidities compared with uninfected individuals. Virus- induced immunosenescence, a process characterized by a progressive decline of immune system function, contributes to the premature ageing observed in HIV patients. Although antiretroviral therapy has significantly improved both the quality and length of patient lives, the life expectancy of treated patients is still shorter compared with that of uninfected individuals. In particular, while antiretroviral therapy can contrast some features of HIV-associated immunosenescence, several anti-HIV agents may themselves contribute to other aspects of immune ageing. Moreover, older HIV patients tend to have a worse immunological response to the antiviral therapy. In this review we will examine the available evidence on the role of antiretroviral therapy in the control of the main features regulating immunosenescence.
References
1.
Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF, High KP: Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47: 542–553.
2.
Cohen J, Torres C: HIV-associated cellular senescence: a contributor to accelerated aging. Ageing Res Rev 2017; 36: 117–124.
3.
Klein RS: Trends related to aging and co-occurring disorders in HIV-infected drug users. Subst Use Misuse 2011; 46: 233–244.
4.
Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ, Samani NJ; West of Scotland Coronary Prevention Study Group: Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369: 107–114.
5.
Takata Y, Kikukawa M, Hanyu H, et al: Association between ApoE phenotypes and telomere erosion in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2012; 67: 330–335.
6.
Deeks SG, Verdin E, McCune JM: Immunosenescence and HIV. Curr Opin Immunol 2012; 24: 501–506.
7.
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al: Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120–1126.
8.
Smith RL, de Boer R, Brul S, Budovskaya Y, van Spek H: Premature and accelerated aging: HIV or HAART? Front Genet 2013; 3: 328.
9.
Dock JN, Effros RB: Role of CD8 T cell replicative senescence in human aging and in HIV-mediated immunosenescence. Aging Dis 2011; 2: 382–397.
10.
Hayflick L: The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614–636.
11.
Zhu Y, Amstrong JL, Tchkonia T, Kirkland JL: Cellular senescence and the senescent secretory phenotype in age-related chronic diseases. Curr Opin Clin Metab Care 2014; 17: 324–328.
12.
Baker DJ, Alimirah F, van Deursen JM, Campisi J, Hildesheim J: Oncogenic senescence: a multi-functional perspective. Oncotarget 2017; 8: 27661–27672.
13.
Salama R, Sadaie M, Hoare M, Narita M: Cellular senescence and its effector programs. Genes Dev 2014; 28: 99–114.
14.
Watanabe S, Kawamoto S, Ohtani N, Hara E: Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. Cancer Sci 2017; 108: 563–569.
15.
Ventura MT, Casciaro M, Gangemi S, Buquicchio R: Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. Clin Mol Allergy 2017; 15: 21.
16.
Goronzy JJ, Weyand CM: Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013; 14: 428–436.
17.
Goronzy JJ, Weyand CM: Immune aging and autoimmunity. Cell Mol Life Sci 2012; 69: 1615–1623.
18.
Franceschi C, Campisi J: Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014; 69(suppl 1):S4–S9.
19.
Fülöp T, Larbi A, Pawelec G: Human T cell aging and the impact of persistent viral infections. Front Immunol 2013; 4: 271.
20.
Nikolich-Žugich J: The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol 2018; 19: 10–19.
21.
Messaoudi I, Lemaoult J, Guevara-Patino JA, Metzner BM, Nikolich-Zugich J: Age-related CD8 T cell clonal expansions constrict CD8 T cell repertoire and have the potential to impair immune defense. J Exp Med 2004; 200: 1347–1358.
22.
Akbar AN, Fletcher JM: Memory T cell homeostasis and senescence during aging. Curr Opin Immunol 2005; 17: 480–485.
23.
Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, Koup RA. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396: 690–695.
24.
Linton PJ, Dorshkind K: Age-related changes in lymphocyte development and function. Nat Immunol 2004; 5: 133–139.
25.
Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyand CM: Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75: 12182–12187.
26.
Effros RB, Boucher N, Porter V, Zhu X, Spaulding C, Walford RL, Kronenberg M, Cohen D, Schächter F: Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 1994; 29: 601–609.
27.
Goronzy JJ, Lee WW, Weyand CM: Aging and T-cell diversity. Exp Gerontol 2007; 42: 400–406.
28.
Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ, Ouslander JG, Weyand CM, Goronzy JJ: T cell subset-specific susceptibility to aging. Clin Immunol 2008; 127: 107–118.
29.
Plunkett FJ, Franzese O, Belaramani LL, Fletcher JM, Gilmour KC, Sharifi R, Khan N, Hislop AD, Cara A, Salmon M, Gaspar HB, Rustin MH, Webster D, Akbar AN: The impact of telomere erosion on memory CD8C T cells in patients with X-linked lymphoproliferative syndrome. Mech Ageing Dev 2005; 126: 855–865.
30.
Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M: Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. Mech Ageing Dev 2006; 127: 274–281.
31.
Plunkett FJ, Franzese O, Finney HM, Fletcher JM, Belaramani LL, Salmon M, Dokal I, Webster D, Lawson AD, Akbar AN: The loss of telomerase activity in highly differentiated CD8+CD28–CD27– T cells is associated with decreased Akt (Ser473) phosphorylation. J Immunol 2007; 178: 7710–7719.
32.
Sathaliyawala T, Kubota M, Yudanin N, Turner D, Camp P, Thome JJ, Bickham KL, Lerner H, Goldstein M, Sykes M, Kato T, Farber DL: Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 2013; 38: 187–197.
33.
Larbi A, Fulop T. From “truly naïve” to “exhausted senescent” T cells: when markers predict functionality. Cytometry A 2014; 85: 25–35.
34.
Ferrando-Martinez S, Ruiz-Mateos E, Leal M: CD27 and CCR7 expression on naive T cells, are both necessary? Immunol Lett 2010; 127: 157–158.
35.
Akbar AN, Henson SM: Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 2011; 11: 289–295.
36.
Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay R, Kipling D, Soares MV, Battistini L, Akbar AN: Reversible senescence in human CD4+CD45RA+CD27– memory T cells. J Immunol 2011; 187: 2093–100.
37.
Henson SM, Riddell NE, Akbar AN: Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol 2012; 24: 476–481.
38.
Boomer JS, Green JM: An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol 2010; 2:a002436.
39.
Agematsu K, Kobata T, Sugita K, Freeman GJ, Beckmann MP, Schlossman SF, Morimoto C: Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27. J Immunol 1994; 153: 1421–1429.
40.
Denoeud J, Moser M: Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol 2011; 89: 195–203.
41.
Henson SM, Franzese O, Macaulay R, Libri V, Azevedo RI, Kiani-Alikhan S,Plunkett FJ, Masters JE, Jackson S, Griffiths SJ, Pircher HP, Soares MV, Akbar AN: KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 2009; 113: 6619–6628.
42.
Blackburn EH: Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005; 579: 859–862.
43.
Hathcock KS, Chiang YJ, Hodes RJ: In vivo regulation of telomerase activity and telomere length. Immunol Rev 2005; 205: 104–113.
44.
Bandrés E, Merino J, Vázquez B, Inogés S, Moreno C, Subirá ML, Sánchez-Ibarrola A: The increase of IFN-γ production through aging correlates with the expanded CD8+highCD28–CD57+ subpopulation. Clin Immunol 2000; 96: 230–235.
45.
Kaech SM, Wherry EJ, Ahmed R: Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2: 251–262.
46.
Strioga M, Pasukoniene V, Characiejus D: CD8+CD28– and CD8+CD57+ T cells and their role in health and disease. Immunology 2011; 134: 17–32.
47.
Merino J, Martınez-González MA, Rubio M, Inogés S, Sánchez-Ibarrola A, Subirá ML: Progressive decrease of CD8high+CD28+CD57– T cells with ageing. Clin Exp Immunol 1998; 112: 48–55.
48.
Brenchley JM, Karandikar NJ, Betts MR, et al: Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101: 2711–2720.
49.
Lanna A, Coutavas E, Levati L, Seidel J, Rustin MH, Henson SM, Akbar AN, Franzese O: IFN-α inhibits telomerase in human CD8+ T cells by both hTERT downregulation and induction of p38 MAPK signaling. J Immunol 2013; 191: 3744–3752.
50.
Henson SM, Lanna A, Riddell NE, Franzese O, Macaulay R, Griffiths SJ, Puleston DJ, Watson AS, Simon AK, Tooze SA, Akbar AN: p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8+ T cells. J Clin Invest 2014; 124: 4004–4016.
51.
Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, Jacobson LP; Multicenter AIDS Cohort Study: Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr 2009; 50: 299–306.
52.
Desai S, Landay A: Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7: 4–10.
53.
Pathai S, Bajillan H, Landay AL, High KP: Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2014; 69: 833–842.
54.
Tsoukas C: Immunosenescence and aging in HIV. Curr Opin HIV AIDS 2014; 9: 398–404.
55.
Appay V, Sauce D: Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214: 231–241.
56.
Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, Mack WJ, Cohen MH, Jacobson L, Gange S: Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45: 1074–1081.
57.
Ikezu T: The aging of human-immunodeficiency-virus-associated neurocognitive disorders. J Neuroimmune Pharmacol 2009; 4: 161–162.
58.
Cao W, Jamieson BD, Hultin LE, et al: Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009; 50: 137–147.
59.
Luz Correa B, Ornaghi AP, Cerutti Muller G, Engroff P, Pestana Lopes R, Gomes da Silva Filho I, Bosch JA, Bonorino C, Bauer ME: The inverted CD4:CD8 ratio is associated with cytomegalovirus, poor cognitive and functional states in older adults. Neuroimmunomodulation 2014; 21: 206–212.
60.
Nikolich-Žugich J: Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J Immunol 2014; 193: 2622–2629.
61.
Nelson JA, Krishnamurthy J, Menezes P, Liu Y, Hudgens MG, Sharpless NE, Eron JJ Jr: Expression of p16INK4a as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell 2012; 11: 916–918.
62.
Karim R, Mack WJ, Stiller T, Operskalski E, Frederick T, Landay A, Young MA, Tien PC, Augenbraun M, Strickler HD, Kovacs A: Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS 2013; 27: 1473–1481.
63.
Keating SM, Jacobs ES, Norris PJ: Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. Cytokine Growth Factor Rev 2012; 23: 193–206.
64.
Navikas V, Link J, Persson C, Olsson T, Höjeberg B, Ljungdahl A, Link H, Wahren B: Increased mRNA expression of IL-6, IL-10, TNF-α, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 484–489.
65.
Norcini Pala A, Steca P, Bagrodia R, Helpman L, Colangeli V, Viale P, Wainberg ML: Subtypes of depressive symptoms and inflammatory biomarkers: an exploratory study on a sample of HIV-positive patients. Brain Behav Immun 2016; 56: 105–113.
66.
Douek DC, Betts MR, Hill BJ, Little SJ, Lempicki R, Metcalf JA, Casazza J, Yoder C, Adelsberger JW, Stevens RA, Baseler MW, Keiser P, Richman DD, Davey RT, Koup RA: Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol 2011; 167: 6663–6638.
67.
Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA: CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995; 95: 2061–2066.
68.
Di Mascio M, Sereti I, Matthews LT, Natarajan V, Adelsberger J, Lempicki R,Yoder C, Jones E, Chow C, Metcalf JA, Sidorov IA, Dimitrov DS, Polis MA, Kovacs JA: Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naïve T-cell depletion. J Virol 2006; 80: 2665–2674.
69.
Desai S, Landay A: Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7: 4–10.
70.
Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, Waters A, Easterbrook P, Dunbar PR, Shepherd D, Cerundolo V, Emery V, Griffiths P, Conlon C, McMichael AJ, Richman DD, Rowland-Jones SL, Appay V: Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004; 2:E20.
71.
Effros RB: Long-term immunological memory against viruses. Mech Ageing Dev 2000; 121: 161–171.
72.
Choremi-Papadopoulou H, Panagiotou N, Samouilidou E, Kontopidou F, Viglis V, Antoniadou A, Kosmidis J, Kordossis T: CD28 costimulation and CD28 expression in T lymphocyte subsets in HIV-1 infection with and without progression to AIDS. Clin Exp Immunol 2000; 119: 499–506.
73.
Gamberg J, Pardoe I, Bowmer MI, Howley C, Grant M: Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression. Immunol Cell Biol 2004; 82: 38–46.
74.
Kämmerer R, Iten A, Frei PC, Bürgisser P: Expansion of T cells negative for CD28 expression in HIV infection. Relation to activation markers and cell adhesion molecules, and correlation with prognostic markers. Med Microbiol Immunol 1996; 185: 19–25.
75.
Hazenberg MD, Otto SA, Cohen Stuart JW, Verschuren MC, Borleffs JC, Boucher CA, Coutinho RA, Lange JM, Rinke de Wit TF, Tsegaye A, van Dongen JJ, Hamann D, de Boer RJ, Miedema F: Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000; 6: 1036–1042.
76.
Appay V, Rowland-Jones SL: Premature ageing of the immune system: the cause of AIDS? Trends Immunol 2002; 23: 580–585.
77.
Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL: HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192: 63–75.
78.
Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA: Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101: 2711–2720.
79.
Lieberman J, Trimble LA, Friedman RS, Lisziewicz J, Lori F, Shankar P, Jessen H: Expansion of CD57 and CD62L–CD45RA+ CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection. AIDS 1999; 13: 891–899.
80.
Booiman T, Wit FW, Girigorie AF, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Franceschi C, Deeks SG, Winston A, Reiss P, Kootstra NA; Co-morBidity in Relation to Aids (COBRA) Collaboration: Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. PLoS One 2017; 12:e0183357.
81.
Palmer LD, Weng N, Levine BL, June CH, Lane HC, Hodes RJ: Telomere length, telome-rase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. J Exp Med 1997; 185: 1381–1386.
82.
Lichterfeld M, Mou D, Cung TD, Williams KL, Waring MT, Huang J, Pereyra F, Trocha A, Freeman GJ, Rosenberg ES, Walker BD, Yu XG: Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 2008; 112: 3679–3687.
83.
Rickabaugh TM, Kilpatrick RD, Hultin LE, Hultin PM, Hausner MA, Sugar CA, Althoff KN, Margolick JB, Rinaldo CR, Detels R, Phair J, Effros RB, Jamieson BD: The dual impact of HIV-1 infection and aging on naive CD4 T cells: additive and distinct patterns of impairment. PLoS One 2011; 6:e16459.
84.
Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, Landay AL, Jaworowski A, Crowe SM: HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26: 843–853.
85.
Ballon G, Ometto L, Righetti E, Cattelan AM, Masiero S, Zanchetta M, Chieco Bianchi L, De Rossi A: Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes. J Infect Dis 2001; 183: 417–424.
86.
Bostik P, Dodd GL, Patel SS, Kadivar H, Ansari AA: Effect of productive in vitro human immunodeficiency virus or simian immunodeficiency virus infection on telomerase activity in lymphoid and nonlymphoid cells. J Infect Dis 2002; 185: 999–1001.
87.
Franzese O, Adamo R, Pollicita M, Comandini A, Laudisi A, Perno CF, Aquaro S, Bonmassar E: Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4+ T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1). J Med Virol 2007; 79: 639–646.
88.
Franzese O, Comandini A, Adamo R, Sgadari C, Ensoli B, Bonmassar E: HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells. Cell Death Differ 2004; 11: 782–784.
89.
Comandini A, Naro C, Adamo R, Akbar AN, Lanna A, Bonmassar E, Franzese O: Molecular mechanisms involved in HIV-1-Tat mediated inhibition of telomerase activity in human CD4+ T lymphocytes. Mol Immunol 2013; 54: 181–192.
90.
Subramanyam M, Gutheil WG, Bachovchin WW, Huber BT: Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J Immunol 1993; 150: 2544–2553.
91.
Benito JM, López M, Lozano S, Martinez P, González-Lahoz J, Soriano V: CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20: 227–233.
92.
Chou JP, Ramirez CM, Wu JE, Effros RB: Accelerated aging in HIV/AIDS: novel biomarkers of senescent human CD8+ T cells. PLoS One 2013; 8:e64702.
93.
Parish ST, Kim S, Sekhon RK, Wu JE, Kawakatsu Y, Effros RB: Adenosine deaminase modulation of telomerase activity and replicative senescence in human CD8 T lymphocytes. J Immunol 2010; 184: 2847–2854.
94.
Muthumani K, Choo AY, Shedlock DJ, Laddy DJ, Sundaram SG, Hirao L, Wu L, Thieu KP, Chung CW, Lankaraman KM, Tebas P, Silvestri G, Weiner DB: Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol 2008; 82: 11536–11544.
95.
Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, Birch KE, Cook JE, Jackson SE, Salmon M, Rustin MH, Akbar AN: Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol 2005; 175: 8218–8225.
96.
Benlahrech A, Patterson S: HIV-1 infection and induction of interferon alpha in plasmacytoid dendritic cells. Curr Opin HIV AIDS 2011; 6: 373–378.
97.
Andrade HB, Shinotsuka CR, da Silva IRF, Donini CS, Yeh Li H, de Carvalho FB, Americano do Brasil PEA, Bozza FA, Miguel Japiassu A: Highly active antiretroviral therapy for critically ill HIV patients: a systematic review and meta-analysis. PLoS One 2017; 12:e0186968.
98.
Qian K, Morris-Natschke SL, Lee KH: HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 2009; 29: 369–393.
99.
Thorlund K, Horwitz MS, Fife BT, Lester R, Cameron DW: Landscape review of current HIV “kick and kill” cure research – some kicking, not enough killing. BMC Infect Dis 2017; 17: 595.
100.
Weber IT, Harrison RW: Decoding HIV resistance: from genotype to therapy. Future Med Chem 2017; 9: 1529–1538.
101.
Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Heath Approach, ed 2. Geneva, WHO, 2016.
102.
Gakhar H, Kamali A, Holodniy M: Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs 2013; 73: 651–672.
103.
Deeks SG, Phillips AN: HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
104.
Antiretroviral Therapy Cohort Collaboration: Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387–1396.
105.
Ripa M, Chiappetta S, Tambussi G: Immunosenescence and hurdles in the clinical management of older HIV-patients. Virulence 2017; 8: 508–528.
106.
Camacho R, Teófilo E: Antiretroviral therapy in treatment-naïve patients with HIV infection. Curr Opin HIV AIDS 2011; 6(suppl 1):S3–S11.
107.
Onen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, Tebas P: Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11: 100–109.
108.
Barbaro G, Barbarini G: Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk. Chemotherapy 2006; 52: 161–165.
109.
Nixon DE, Landay AL: Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010; 5: 498–503.
110.
Keating SM, Golub ET, Nowicki M, Young M, Anastos K, Crystal H, Cohen MH, Zhang J, Greenblatt RM, Desai S, Wu S, Landay AL, Gange SJ, Norris PJ; Women’s Interagency HIV Study: The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011; 25: 1823–1832.
111.
Albino E, Godoy L, Hill M: Markers of chronic immune activation in HIV patients receiving antiretroviral therapy. J Immunol 2016; 196(suppl 1): 217.39
112.
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365–1371.
113.
Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, Alfano M, Poli G, Rossouw T: Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010; 202: 723–733.
114.
Marchetti G, Tincati C, Silvestri G: Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013; 26: 2–18.
115.
Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM: HIV as a cause of immune activation and immunosenescence. Mediators Inflamm 2017; 2017: 6825493.
116.
Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, Martínez-Maza O, Bream JH: The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015; 29: 463–471.
117.
Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, O’Connell RJ, Rupert A, Chomont N, Valcour V, Kim JH, Robb ML, Michael NL, Douek DC, Ananworanich J, Utay NS; RV254/SEARCH 010, RV304/SEARCH 013 and SEARCH 011 Protocol Teams: Persistent, albeit reduced, chronic inflammation in parsons starting antiretroviral therapy in acute HIV infection. Clin Infect Dis 2017; 64: 124–131.
118.
Srivastava S: The mitochondrial basis of aging and age-related disorders. Genes (Basel) 2017; 8: 398.
119.
Chou JP, Effros RB: T cell replicative senescence in human aging. Curr Pharm Des 2013; 19: 1680–1698.
120.
Schapira AH: Mitochondrial diseases. Lancet 2012; 379: 1825–1834.
121.
Cline SD: Mitochondrial DNA damage and its consequences for mitochondrial gene expression. Biochim Biophys Acta 2012; 1819: 979–991.
122.
Lightowlers RN, Taylor RW, Turnbull DM: Mutations causing mitochondrial disease: what is new and what challenges remain? Science 2015; 349: 1494–1499.
123.
Park CB, Larsson NG: Mitochondrial DNA mutations in disease and aging. J Cell Biol 2011; 193: 809–818.
124.
Copeland WC: The mitochondrial DNA polymerase in health and disease. Subcell Biochem 2010; 50: 211–222.
125.
Lewis W, Dalakas MC: Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1: 417–1422.
126.
Maagaard A, Kvale D: Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother 2009; 64: 901–909.
127.
Smith RL, Tan JME, Jonker M, Jongejan A, Buissink T, Veldhuijzen S, van Kampen AHC, Brul S, van der Spek H: Beyond the polymerase-γ theory: production of ROS as a mode of NRTI-induced mitochondrial toxicity. PLoS One 2017; 12:e0187424.
128.
Elias A, Nelson B, Oputiri D, Geoffrey OB P: Antiretroviral toxicity and oxidative stress. Am J Pharmacol Toxicol 2013; 8: 187–196.
129.
Wang D, Melancon JK, Verbesey J, et al: Microvascular endothelial dysfunction and enhanced thromboxane and endothelial contractility in patients with HIV. J AIDS Clin Res 2013; 4: 267.
130.
Williams AA, Sitole LJ, Meyer D: HIV/HAART-associated oxidative stress is detectable by metabonomics. Mol Biosyst 2017; 13: 2202–2217.
131.
Caron-Debarle M, Boccara F, Lagathu C, Antoine B, Cervera P, Bastard JP, Vigouroux C, Capeau J: Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr Pharm Des 2010; 16: 3352–3360.
132.
Pinti M, Gibellini L, Guaraldi G, Orlando G, Gant TW, Morselli E, Nasi M, Salomoni P, Mussini C, Cossarizza A: Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease. AIDS 2010; 24: 841–850.
133.
Nsagha DS, Assob JC, Njunda AL, Tanue EA, Kibu OD, Ayima CW, Ngowe MN: Risk factors of cardiovascular diseases in HIV/AIDS patients on HAART. Open AIDS J 2015; 9: 51–59.
134.
Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J: Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003; 17: 2437–2444.
135.
Lefèvre C, Auclair M, Boccara F, Bastard JP, Capeau J, Vigouroux C, Caron-Debarle M: Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol 2010; 30: 2611–2620.
136.
Mattout A, Dechat T, Adam SA, Goldman RD, Gruenbaum Y: Nuclear lamins, diseases and aging. Curr Opin Cell Biol 2006; 18: 335–341.
137.
Schreiber KH, Kennedy BK: When lamins go bad: nuclear structure and disease. Cell 2013; 152: 1365–1375.
138.
Bruston F, Delbarre E, Ostlund C, Worman HJ, Buendia B, Duband-Goulet I: Loss of a DNA binding site within the tail of prelamin A contributes to altered heterochromatin anchorage by progerin. FEBS Lett 2010; 584: 2999–3004.
139.
Rocha-Perugini V, González-Granado JM: Nuclear envelope lamin-A as a coordinator of T cell activation. Nucleus 2014; 5: 396–401.
140.
Lu W, Andrieu JM: HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood 2000; 96: 250–258.
141.
Franzese O, Lombardi A, Comandini A, Cannavò E, Testorelli C, Cirello I, Bonmassar E: Effect of saquinavir on proliferation and telomerase activity of human peripheral blood mononuclear cells. Life Sci 2001; 69: 1509–1520.
142.
Lehmann C, Jung N, Hofmann A, Cornely OA, Wyen C, Fätkenheuer G, Hartmann P: Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression. Curr HIV Res 2008; 6: 555–559.
143.
Delmonte OM, Bertolotto G, Ricotti E, Tovo PA: Immunomodulatory effects of two HIV protease inhibitors, saquinavir and ritonavir, on lymphocytes from healthy seronegative individuals Immunol Lett 2007; 111: 111–115.
144.
Lange C, Lederman M, Madero J, Medvik K, Asaad R, Pacheko C, Carranza C, Valdez H: Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr 2002; 30: 33–40.
145.
Hunt P, Sinclair E, Epling L, Teague J, Tan QX, Martin, Lum P, Deeks S: T-cell senescence and proliferation defects persist in treated HIV-infected individuals maintaining viral suppression and are associated with poor CD4+ T-cell recovery (abstract). Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 16–19, 2010.
146.
Desai S, Ronquillo R, Usuga X, Martinson J, Adeyemi O, Tenorio A, Landay A: Immune senescence, activation, and abnormal T-cell homeostasis despite effective HAART, a hallmark of early aging in HIV disease (abstract 381). Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 8–11, 2009.
147.
Valdez H, Connick E, Smith K, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay A; AIDS Clinical Trials Group Protocol 375 Team: Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16: 1859–1866.
148.
Tassiopoulos K, Landay A, Collier AC, Connick E, Deeks SG, Hunt P, Lewis DE, Wil son C, Bosch R: CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis 2012; 205: 1730–1738.
149.
Mojumdar K, Vajpayee M, Chauhan NK, Singh A, Singh R, Kurapati S: Altered T cell differentiation associated with loss of CD27 and CD28 in HIV infected Indian individuals. Cytometry B Clin Cytom 2012; 82: 43–53.
150.
Eberhard JM, Ahmad F, Hong HS, Bhatnagar N, Keudel P, Schulze Zur Wiesch J, Schmidt RE, Meyer-Olson D: Partial recovery of senescence and differentiation disturbances in CD8+ T cell effector-memory cells in HIV-1 infection after initiation of antiretroviral treatment. Clin Exp Immunol 2016; 186: 227–238.
151.
Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R: Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003; 4: 1191–1198.
152.
Boutboul F, Puthier D, Appay V, Pellé O, Ait-Mohand H, Combadière B, Carcelain G, Katlama C, Rowland-Jones SL, Debré P, Nguyen C, Autran B: Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS 2005; 19: 1981–1986.
153.
Adland E, Klenerman P, Goulder P, Matthews PC: Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. Front Microbiol 2015; 6: 1016.
154.
Effros RB: The silent war of CMV in aging and HIV infection. Mech Ageing Dev 2016; 158: 46–52.
155.
Young MJ: Off-target effects of drugs that disrupt human mitochondrial DNA maintenance. Front Mol Biosci 2017; 4: 74.
156.
Strahl C, Blackburn EH: Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996; 16: 53–65.
157.
Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St Claire ME, Poirier MC: Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys, J Acquir Immune Defic Syndr 2002; 29: 323–329.
158.
Liu X, Inomata M, Ogawara T, Saneyoshi M, Yamaguchi T: Telomere shortening in human HL60 cells by treatment with 3′-azido-2′,3′-dideoxynucleosides and telomerase inhibition by their 5′-triphosphates. Nucleosides Nucleotides Nucleic Acids 2007; 26: 1067–1071.
159.
Liu X, Takahashi H, Harada Y, Ogawara T, Ogimura Y, Mizushina Y, Saneyoshi M, Yamaguchi T: 3′-Azido-2′,3′-dideoxynucleoside 5′-triphosphates inhibit telomerase activity in vitro, and the corresponding nucleosides cause telomere shortening in human HL60 cells. Nucleic Acids Res 2007; 35: 7140–7149.
160.
Rossi A, Russo G, Puca A, La Montagna R, Caputo M, Mattioli E, Lopez M, Giordano A, Pentimalli F: The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. Int J Cancer 2009; 125: 235–243.
161.
Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, Spelman T, Hearps A, Fairley C, Smit de V, Pierce AB, Armishaw J, Crowe SM, Cooper DA, Koelsch KK, Liu JP, Chuah J, Lewin SR: Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis 2013; 207: 1157–1165.
162.
Opresko PL, Shay JW: Telomere-associated aging disorders. Ageing Res Rev 2017; 33: 52–66.
163.
Imam T, Jitratkosol MH, Soudeyns H, Sattha B, Gadawski I, Maan E, Forbes JC, Alimenti A, Lapointe N, Lamarre V, Money DM, Côté HC; CIHR Emerging Team Grant on HIV Therapy and Aging: CARMA: Leukocyte telomere length in HIV-infected pregnant women treated with antiretroviral drugs during pregnancy and their uninfected infants. J Acquir Immune Defic Syndr 2012; 60: 495–502.
164.
Palmer LD, Weng N, Levine BL, June CH, Lane HC, Hodes RJ: Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. J Exp Med 1997; 185: 1381–1386.
165.
Wolthers KC, Otto SA, Wisman GB, Fleury S, Reiss P, ten Kate RW, van der Zee AG, Miedema F: Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection. Blood 1999; 93: 1011–1019.
166.
Adamo R, Comandini A, Aquino A, Bonmassar L, Guglielmi L, Bonmassar E, Franzese O: The antiretroviral agent saquinavir enhances hTERT expression and telome-rase activity in human T leukaemia cells in vitro. J Exp Clin Cancer Res 2013; 32: 38.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
